Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Heeyoung | - |
dc.contributor.author | Kim, EunYoung | - |
dc.date.accessioned | 2022-01-13T01:44:16Z | - |
dc.date.available | 2022-01-13T01:44:16Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.issn | 1976-3786 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/53395 | - |
dc.description.abstract | Alzheimer's disease (AD) is a complex, progressive, neurodegenerative disorder. As with other common chronic diseases, multiple risk factors contribute to the onset and progression of AD. Many researchers have evaluated the epidemiologic and pathophysiological association between AD, cardiovascular diseases (CVDs), and cerebrovascular diseases (CBVDs), including commonly reported risk factors such as diabetes, hypertension, and dyslipidemia. Relevant therapies of CVDs/CBVDs for the attenuation of AD have also been empirically investigated. Considering the challenges of new drug development, in terms of cost and time, multifactorial approaches such as therapeutic repositioning of CVD/CBVD medication should be explored to delay the onset and progression of AD. Thus, in this review, we discuss our current understanding of the association between cardiovascular risk factors and AD, as revealed by clinical and non-clinical studies, as well as the therapeutic implications of CVD/CBVD medication that may attenuate AD. Furthermore, we discuss future directions by evaluating ongoing trials in the field. | - |
dc.format.extent | 29 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.title | Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12272-020-01268-5 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.43, no.9, pp 932 - 960 | - |
dc.identifier.kciid | ART002627601 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000567737200001 | - |
dc.identifier.scopusid | 2-s2.0-85091383057 | - |
dc.citation.endPage | 960 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 932 | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 43 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Alzheimer's disease | - |
dc.subject.keywordAuthor | Cardiovascular disease | - |
dc.subject.keywordAuthor | Cerebrovascular disease | - |
dc.subject.keywordAuthor | Pharmacotherapeutic implications | - |
dc.subject.keywordAuthor | Drug repositioning | - |
dc.subject.keywordPlus | RENIN-ANGIOTENSIN SYSTEM | - |
dc.subject.keywordPlus | CONVERTING ENZYME-INHIBITORS | - |
dc.subject.keywordPlus | BRAIN MITOCHONDRIAL-FUNCTION | - |
dc.subject.keywordPlus | MILD COGNITIVE IMPAIRMENT | - |
dc.subject.keywordPlus | GROWTH-FACTOR-I | - |
dc.subject.keywordPlus | A-BETA | - |
dc.subject.keywordPlus | ATRIAL-FIBRILLATION | - |
dc.subject.keywordPlus | MEMORY IMPAIRMENT | - |
dc.subject.keywordPlus | HEART-FAILURE | - |
dc.subject.keywordPlus | OXIDATIVE STRESS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.